Design, synthesis, and biological evaluation of novel dual FFA1 (GPR40)/PPARδ agonists as potential anti-diabetic agents.
Sign Up to like & getrecommendations! Published in 2019 at "Bioorganic chemistry"
DOI: 10.1016/j.bioorg.2019.103254
Abstract: The free fatty acid receptor 1 (FFA1) and peroxisome proliferator-activated receptor δ (PPARδ) were considered as potential anti-diabetic targets, and the dual FFA1/PPARδ agonists might provide synergistic effect in insulin secretion and sensibility. Herein, we… read more here.
Keywords: ppar; ppar agonists; ffa1; potential anti ... See more keywords
The roles of PPARγ and its agonists in autoimmune diseases: A comprehensive review
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Autoimmunity"
DOI: 10.1016/j.jaut.2020.102510
Abstract: Abstract Autoimmune diseases are common diseases of the immune system that are characterized by the loss of self-tolerance and the production of autoantibodies; the breakdown of immune tolerance and the prolonged inflammatory reaction are undisputedly… read more here.
Keywords: ppar agonists; ppar ppar; roles ppar; autoimmune diseases ... See more keywords
Differential effects of selective- and pan-PPAR agonists on experimental steatohepatitis and hepatic macrophages.
Sign Up to like & getrecommendations! Published in 2020 at "Journal of hepatology"
DOI: 10.1016/j.jhep.2020.04.025
Abstract: BACKGROUND AND AIMS Peroxisome proliferator-activated receptors (PPARs) are essential regulators of whole-body metabolism, but also modulate inflammation in immune cells, notably macrophages. We compared selective PPAR agonists with the pan-PPAR agonist lanifibranor as therapeutic agents… read more here.
Keywords: ppar; ppar agonists; hepatic macrophages; pan ppar ... See more keywords
Synthesis of a unique dimethyl thiazoline containing intermediate of novel peroxisome proliferator-activated receptors(PPAR)δ agonists
Sign Up to like & getrecommendations! Published in 2018 at "Tetrahedron Letters"
DOI: 10.1016/j.tetlet.2018.10.051
Abstract: Abstract Peroxisome proliferator-activated receptor delta (PPARδ) is considered as a promising biological target for the development of new drugs to treat metabolic syndrome including hyperlipidemia. In this study, a simple and efficient method for the… read more here.
Keywords: peroxisome proliferator; ppar agonists; dimethyl; proliferator activated ... See more keywords
PPARγ agonists delay age‐associated metabolic disease and extend longevity
Sign Up to like & getrecommendations! Published in 2020 at "Aging Cell"
DOI: 10.1111/acel.13267
Abstract: Aging leads to a number of disorders caused by cellular senescence, tissue damage, and organ dysfunction. It has been reported that anti‐inflammatory and insulin‐sensitizing compounds delay, or reverse, the aging process and prevent metabolic disorders,… read more here.
Keywords: ppar agonists; longevity; age; disease ... See more keywords
Is pulmonary vascular disease reversible with PPAR ɣ agonists?
Sign Up to like & getrecommendations! Published in 2018 at "Microcirculation"
DOI: 10.1111/micc.12444
Abstract: Severe angio‐obliterative PAH remains a disease characterized by great morbidity and shortened survival. Unfortunately, the only currently available treatments for angio‐obliterative changes are palliative in the form of pulmonary vasodilators evolving from the phosphodiesterase inhibitor… read more here.
Keywords: ppar; ppar agonists; angio obliterative; vascular disease ... See more keywords
Peroxisome Proliferator-Activated Receptor (PPAR) Gamma Agonists as Therapeutic Agents for Cardiovascular Disorders: Focus on Atherosclerosis.
Sign Up to like & getrecommendations! Published in 2017 at "Current pharmaceutical design"
DOI: 10.2174/1381612823666161118145850
Abstract: Peroxisome proliferation-activated receptors (PPARs) are ligand-activated transcription factors that mainly regulate genes responsible for fatty acid (FA) and energy metabolism. There are three members of the PPAR family, PPAR-α, PPAR- β/δ and PPAR-γ. All three… read more here.
Keywords: ppar; peroxisome proliferator; ppar agonists; treatment ... See more keywords
Novel Cinnamic Acid Derivatives as Potential PPARδ Agonists for Metabolic Syndrome: Design, Synthesis, Evaluation and Docking Studies.
Sign Up to like & getrecommendations! Published in 2019 at "Current drug discovery technologies"
DOI: 10.2174/1570163816666190314124543
Abstract: Peroxisome proliferator-activated receptor (PPAR) δ is expressed universally in the entire tissues, particularly in those concerned with the lipid metabolism. PPAR δ stimulation alters body's energy fuel preference to fat from glucose and shows up… read more here.
Keywords: ppar; ppar agonists; novel cinnamic; cinnamic acid ... See more keywords
Hydroxy Cinnamic Acid Derivatives as Partial PPARγ Agonists: In silico Studies, Synthesis and Biological Characterization Against Chronic Myeloid Leukemia Cell Line (K562).
Sign Up to like & getrecommendations! Published in 2017 at "Anti-cancer agents in medicinal chemistry"
DOI: 10.2174/1871520616666160607010156
Abstract: BACKGROUND Peroxisome proliferator-activated receptor gamma (PPARγ) is a nuclear receptor that regulates the expression of many genes relevant to carcinogenesis. By analogy to selective estrogen receptor modulator for treatment of cancer, selective or partial PPARγ… read more here.
Keywords: ppar; ppar agonists; acid derivatives; partial ppar ... See more keywords
Mechanistic Studies and a Retrospective Cohort Study: The Interaction between PPAR Agonists and Immunomodulatory Agents in Multiple Myeloma
Sign Up to like & getrecommendations! Published in 2022 at "Cancers"
DOI: 10.3390/cancers14215272
Abstract: Simple Summary Cereblon (CRBN) is a direct binding target of immunomodulatory drugs (IMiDs) that are commonly used to treat multiple myeloma (MM). Many patients with MM have comorbidities, including diabetes and/or dyslipidemia, and are treated… read more here.
Keywords: methylation; ppar; ppar agonists; multiple myeloma ... See more keywords
PPAR Agonists and Metabolic Syndrome: An Established Role?
Sign Up to like & getrecommendations! Published in 2018 at "International Journal of Molecular Sciences"
DOI: 10.3390/ijms19041197
Abstract: Therapeutic approaches to metabolic syndrome (MetS) are numerous and may target lipoproteins, blood pressure or anthropometric indices. Peroxisome proliferator-activated receptors (PPARs) are involved in the metabolic regulation of lipid and lipoprotein levels, i.e., triglycerides (TGs),… read more here.
Keywords: ppar agonists; agonists metabolic; syndrome established; metabolic syndrome ... See more keywords